Pre-chemotherapy screening investigations
The work-up before systemic anticancer therapy, with worked results; baseline bloods and ADDIKD kidney function, universal hepatitis B screening and who needs prophylaxis, HIV, HCV, Strongyloides and TB, DPYD genotyping, cardiac, hearing and lung baselines by drug, pregnancy, fertility, dental review and vaccination.
Tier 2Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Screening before systemic therapy answers four questions: can the patient tolerate it (organ function, performance status), will it reactivate something (HBV, Strongyloides, TB), does a gene or baseline test change the dose (DPYD, eGFR, LVEF), and what must happen before day 1 (fertility, pregnancy test, dental work, vaccines, venous access).
- Each eviQ protocol lists its own pre-treatment evaluation. This note covers the logic so you can work out the list for any regimen.
- Most of it is time-critical but shouldn't delay urgent treatment. Hepatitis B results, for example, can follow the first dose if prophylaxis starts promptly.
Loading the rest of the note…
Finished reading?
Sources
- eviQ Cancer Treatments Online (protocol pre-treatment evaluation, day-of-treatment assessment, hepatitis B screening and prophylaxis)AU/NZCancer Institute NSW
- Sandhu G et al. Aligning kidney function assessment in patients with cancer to global practices in internal medicine (International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction, ADDIKD, part 1). EClinicalMedicine 2025;82:103102AU/NZCancer Institute NSW ADDIKD Working Group (EClinicalMedicine), 2025
- Hwang JP et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol 2020;38:3698-715American Society of Clinical Oncology, 2020 (current, November 2026)
- Ali FS et al. AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals. Gastroenterology 2025;168:267-84American Gastroenterological Association, 2025
- MBS item 73322: DPYD genotyping for fluoropyrimidine therapyAU/NZAustralian Government Department of Health, Disability and Ageing, 1 November 2025
- Rosas-Alonso R et al. DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger. Front Pharmacol 2025;16:1645188Frontiers in Pharmacology, 2025
- Lyon AR et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J 2022;43:4229-361European Society of Cardiology, 2022 (current, November 2026)
- Australian Immunisation Handbook: vaccination for people who are immunocompromisedAU/NZAustralian Technical Advisory Group on Immunisation, Department of Health, Disability and Ageing
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Personal emails, About story and Australian-style copy